Clinical trials: Coccidioides Immitis Infection
Cryptosporidium Infection, Cryptosporidiosis
Study of Efficacy and Safety of ABO809 in Healthy Participants
The purpose of this Phase I controlled human infection model (CHIM) study was to determine if oral administration of a good manufacturing practice (GMP) supply of Cryptosporidium parvum oocysts (ABO809) to healthy volunteers…
- Trial name
- NCT05036668
- Testing
- Cryptosporidium parvum oocysts (ABO809)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Rift Valley Fever
Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the…
- Trial name
- MP-12 (NCT00415051)
- Testing
- RVF MP-12
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Coccidioidomycosis
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
This is a Phase IV randomized, double-blinded, placebo-controlled study in 1000 individuals aged 18 years or older, with community acquired pneumonia (CAP) who meet all eligibility criteria in endemic regions.
- Trial name
- NCT02663674
- Testing
- Fluconazole
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cryptosporidium; Diarrhea, Cryptosporidiosis
Trial of Ceramic Water Filters to Reduce Cryptosporidium Infection in Kenya
The aim of the study is to examine the efficacy of ceramic water filters to reduce the burden of waterborne diarrheal illness among infants in selected villages in Kenya.
- Conditions
- Cryptosporidium; Diarrhea, Cryptosporidiosis, Communicable Diseases, Diarrheal Disease
- Trial name
- NCT01695304
- Testing
- Ceramic water filter
- Where
- Kenya
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Coccidioidomycosis
POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
To evaluate the safety of posaconazole (POS) in the treatment of coccidioidomycosis. Period A consisted of 2 blinded arms, posaconazole and fluconazole.
- Trial name
- NCT00423267
- Testing
- Posaconazole, Fluconazole
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Invasive Fungal Infections
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
This is a prospective, multi-center, randomized, open-label parallel arm study involving patients with proven or probable invasive endemic fungal infection to ascertain the pharmacokinetics, safety, efficacy, tolerability and…
- Trial name
- MSG15 (NCT03572049)
- Testing
- SUBA itraconazole, Conventional itraconazole
- Where
- 12 sites in United States, Panama
- Volunteers
- 88 people
- Sponsor
- University of Alabama at Birmingham
Invasive Fungal Infections
Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
A study to evaluate olorofim (F901318) for the treatment of invasive fungal infections in participants lacking suitable alternative treatment options.
- Trial name
- FORMULA-OLS (NCT03583164)
- Testing
- Olorofim
- Where
- 82 sites in United States, Australia and 15 more
- Volunteers
- 203 people
- Sponsor
- F2G Biotech GmbH
Malaria, Malaria Vaccines
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
GSK Biologicals in partnership with the Malaria Vaccine Initiative at PATH is developing a candidate malaria vaccine GSK 257049 for the routine immunization of infants and children living in malaria endemic areas.
- Trial name
- NCT00289185
- Testing
- RTS,S/AS02D, Engerix-B®, TETRActHib™
- Where
- Tanzania
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Toxoplasmosis
Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects
Pyrimethamine in combination with a sulphonamide is known to be effective in the treatment of toxoplasmosis. However, Pyrimethamine has not been approved by the Japanese regulatory body (Pharmaceutical and Medical Devices Agency…
- Trial name
- NCT03258762
- Testing
- Pyrimethamine, Calcium folinate
- Where
- Australia
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coccidioidomycosis
Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment
The purpose of this study is to determine if nikkomycin Z is safe when administered at different dose levels for 14 days. The study will also determine blood levels and urinary excretion of nikkomycin Z in relation to dose…
- Trial name
- NCT00614666
- Testing
- nikkomycin Z
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arizona
Coccidioidomycosis
Safety and Pharmacokinetics of VT-1598
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study in healthy adult subjects ages 18 - 45 years inclusive. It is designed to evaluate the safety and PK of single oral doses of VT-1598.
- Trial name
- NCT04208321
- Testing
- VT-1598
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rift Valley Fever
Safety and Immunogenicity Study of Rift Valley Fever Vaccine
This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine
- Trial name
- RVF (NCT00584194)
- Testing
- TSI-GSD 200 RVF Vaccine
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command